Valley Fever in Dogs: Symptoms, Diagnosis, Treatment, and Geographic Guide
This article is reviewed for clinical accuracy. Always consult your veterinarian for diagnosis and treatment.
Key Takeaways
- Valley fever in dogs is caused by Coccidioides immitis (endemic to California’s San Joaquin Valley and the southern California desert) and the closely related species Coccidioides posadasii (endemic to Arizona, New Mexico, west Texas, Nevada, Utah, and northern Mexico); both species are phylogenetically and clinically nearly identical, and species-level distinction requires molecular typing that is not clinically necessary for treatment decisions; the term “valley fever” is a lay name, while the medical term is coccidioidomycosis; unlike Histoplasma and Blastomyces (which are dimorphic fungi with a mold form in the environment and a yeast form in tissue), Coccidioides has a unique three-stage life cycle: in soil it grows as hyphae that segment into barrel-shaped arthroconidia (arthrospores), which are the infectious environmental particles; in host tissue, inhaled arthroconidia swell into large spherules (20 to 200 micrometers in diameter, far larger than Blastomyces yeast); inside the spherule, hundreds of endospores (2 to 5 micrometers each) develop; when a mature spherule ruptures, it releases endospores into surrounding tissue, each of which can develop into a new spherule, propagating infection throughout the affected organ; this spherule-endospore cycle in tissue is the pathogenic mechanism and is unique among the pathogenic dimorphic fungi.
- The geographic distribution of coccidioidomycosis is entirely distinct from blastomycosis and histoplasmosis: instead of the moist river valleys of the Midwest and Southeast, Coccidioides thrives in the hot, dry, alkaline soils of the Lower Sonoran Life Zone desert, characterized by temperatures that frequently exceed 100 degrees Fahrenheit, low annual rainfall (below 20 inches), and specific soil types with high salt content; the geographic core includes the San Joaquin Valley of California (the origin of the “valley fever” name), the Sonoran Desert of southern Arizona (including the Phoenix and Tucson metropolitan areas, where coccidioidomycosis is among the most common infectious diseases of dogs and humans), the Chihuahuan Desert of New Mexico and west Texas, the Mojave Desert of southern California and Nevada, and northern Mexico (Sonora and Baja California); Arizona carries the highest burden of coccidioidomycosis cases for both dogs and humans in the United States, with tens of thousands of dogs infected annually in the Phoenix metropolitan area alone.
- Dogs inhale Coccidioides arthroconidia from soil dust; the single most important risk factor is proximity to disturbed soil in endemic areas: construction sites (Arizona and California have enormous ongoing residential and commercial construction), agricultural tilling, digging activities, dust storms (haboobs) that suspend soil particles, and desert hiking on trails where dogs disturb the soil surface; approximately 70 percent of dogs in highly endemic areas (central Arizona) are seropositive by adulthood, indicating that most dogs exposed in endemic areas mount an immune response and self-limit infection without clinical illness; only approximately 5 to 10 percent of infected dogs develop clinically apparent disease; the dogs that develop severe or disseminated disease likely have quantitative differences in the inhaled inoculum, subtle immunological variation, or concurrent illness that impairs the cell-mediated immune response that normally contains the primary pulmonary infection.
- The primary clinical presentation in most dogs with symptomatic coccidioidomycosis is respiratory illness (cough, fever, lethargy, decreased appetite) resembling community-acquired pneumonia; however, the feature that most distinguishes canine coccidioidomycosis from other respiratory infections is the high rate of extrapulmonary dissemination, particularly to the skeletal system; bone dissemination (osseous coccidioidomycosis) occurs in an estimated 20 to 30 percent of dogs with symptomatic disease and produces a characteristic clinical picture: lameness that localizes to specific long bones or vertebrae, visible soft tissue swelling over affected bones, draining skin tracts over bony lesions (from lytic bone lesions that extend through the cortex to the skin surface), and a radiographic pattern of aggressive bone destruction with periosteal reaction that is often misdiagnosed as primary bone cancer (osteosarcoma) or other bone tumors; the distal radius, distal ulna, distal tibia, carpus, tarsus, and vertebral bodies are the most commonly affected skeletal sites.
- Diagnosis of coccidioidomycosis relies primarily on serology: the Coccidioides antibody AGID (agar gel immunodiffusion) test and complement fixation (CF) titer are the most widely used serological assays; the AGID detects IgM (early infection) and IgG (later and chronic infection) antibodies separately; AGID IgM positivity indicates recent or active infection; AGID IgG and/or CF titers indicate established or chronic infection; high CF titers (above 1:16 or 1:32) correlate with more severe or disseminated disease; serial CF titers are used to monitor treatment response (declining titers indicate improvement, rising titers indicate treatment failure or relapse); a urine or serum Coccidioides antigen EIA is available from MiraVista Diagnostics and provides additional sensitivity, particularly in dogs with severe immunosuppression who may be seronegative despite active infection; direct visualization of the organism (spherules in cytology or histopathology from affected tissues, draining wounds, or bronchoscopic samples) provides definitive diagnosis.
- Fluconazole is the first-line treatment for coccidioidomycosis in dogs, in contrast to blastomycosis and histoplasmosis where itraconazole is preferred; the standard fluconazole dosage is 5 to 10 mg/kg orally once daily for a minimum of 6 months for pulmonary disease and 12 months or longer for disseminated (bone, CNS) disease; fluconazole is preferred over itraconazole for coccidioidomycosis because it has excellent oral bioavailability without food requirements, superior CNS and bone penetration (critical for the most common dissemination sites), and a more favorable side effect profile in dogs; itraconazole is an alternative for dogs that do not tolerate fluconazole; amphotericin B is reserved for severe rapidly progressive or CNS disease; many dogs with osseous coccidioidomycosis require 12 to 24 months of treatment, and some may require lifelong suppressive therapy to prevent relapse, particularly those with spinal involvement; treatment endpoints are based on clinical resolution, radiographic improvement of bone lesions, and declining serological titers rather than a fixed time frame.
The 4-year-old Weimaraner had been lame on his right front leg for three weeks when he arrived at the orthopedic service in Tucson, Arizona. The referring radiographs showed aggressive periosteal reaction and cortical lysis of the distal radius with marked soft tissue swelling over the carpus; the pattern was described as “highly concerning for primary bone neoplasia, possibly osteosarcoma.” The owner had already been counseled about amputation. On examination, there was a small draining tract over the most prominent lytic area. Cytology of the draining material showed a single large spherule packed with dozens of small endospores. Coccidioides AGID serology returned positive for both IgM and IgG with a CF titer of 1:32. Fluconazole was started and the limb was saved. At the 6-month recheck, the lytic lesion had filled in with new bone and the CF titer had fallen to 1:4.
The Organism: Unique Spherule-Endospore Life Cycle
Coccidioides immitis and C. posadasii have a life cycle fundamentally different from the other dimorphic fungi:
| Stage | Location | Morphology | Role |
|---|---|---|---|
| Hyphal/Arthroconidial stage | Desert soil at ambient temperature | Septate hyphae that fragment into barrel-shaped arthroconidia (2 to 4 micrometers wide, 3 to 6 micrometers long); adjacent empty hyphal cells give a “railroad track” appearance between viable arthroconidia | Environmental survival form; arthroconidia are the infectious particles inhaled by dogs and humans; extremely lightweight and remain airborne for extended distances after soil disturbance |
| Spherule stage (early) | Host tissue (lungs, other organs) at 37 degrees Celsius | Inhaled arthroconidia enlarge into immature spherules (20 to 60 micrometers); nuclear and cytoplasmic division proceeds within the spherule wall | Transition phase; spherule wall is thick and resistant to host immune attack during early development |
| Spherule stage (mature) with endospores | Host tissue | Mature spherule (60 to 200 micrometers; may reach 400 micrometers in immunosuppressed hosts); contains hundreds of individual endospores (2 to 5 micrometers) visible on histopathology as a “bag of marbles” appearance | Rupture releases endospores into surrounding tissue; each endospore develops into a new spherule, propagating infection locally and through lymphatic/hematogenous dissemination |
| Released endospores | Host tissue | Small round cells (2 to 5 micrometers) briefly extracellular after spherule rupture | Each endospore can develop into a new spherule; the moment of spherule rupture triggers a robust pyogranulomatous inflammatory response that causes much of the clinical pathology at affected sites |
Geographic Distribution and Exposure Risk
| Region | States/Areas | Risk Level for Dogs |
|---|---|---|
| Sonoran Desert (Arizona) | Phoenix, Tucson, Scottsdale, Tempe, Chandler, Mesa, Yuma, and surrounding areas; essentially all of Maricopa, Pinal, Pima, and Yuma counties | Extremely high; Arizona reports more human and canine coccidioidomycosis cases than any other US state; up to 70 percent of adult dogs in central Arizona are seropositive |
| San Joaquin Valley (California) | Kern, Tulare, Kings, Fresno, and Madera counties; Bakersfield area; also Ventura and Los Angeles county desert margins | Very high; the “valley fever” name originated here; heavily agricultural area where soil disturbance is constant |
| Mojave/Southern California desert | San Bernardino County desert regions, Riverside County, Imperial County; Palm Springs area | High; growing residential development in desert areas increases human and canine exposure |
| Chihuahuan Desert (New Mexico/Texas) | Southeastern New Mexico (Eddy, Lea, Chaves counties), El Paso area and west Texas, Big Bend region | Moderate to high; C. posadasii dominant; cases increasing as awareness improves |
| Great Basin Desert (Nevada/Utah) | Southern Nevada (Las Vegas area), southwestern Utah (St. George area) | Moderate; increasing case recognition; rapid residential expansion in Las Vegas area increases soil disturbance |
| Northern Mexico (travel cases) | Sonora and Baja California states | Very high in endemic areas; dogs imported from or traveling to these regions |
The geographic range of coccidioidomycosis is expanding northward and eastward; climate data show range expansion of the endemic zone into areas of Oregon, Washington, and Idaho that previously had no endemic disease; veterinarians in historically non-endemic areas are increasingly encountering coccidioidomycosis in dogs that have traveled to or recently relocated from the Southwest.
Clinical Signs by System
| System | Clinical Signs | Frequency |
|---|---|---|
| Respiratory (primary) | Dry or productive cough; fever (103 to 105 degrees Fahrenheit); exercise intolerance; harsh lung sounds; tachypnea; in severe cases, respiratory distress; thoracic radiographs may show focal or diffuse interstitial/alveolar infiltrate; hilar lymphadenopathy is common | Most common presenting complaint; present in approximately 60 to 80 percent of symptomatic cases |
| Skeletal (bone dissemination) | Lameness; soft tissue swelling over affected bone; pain on palpation of affected site; draining skin tracts over lytic bony lesions; appendicular skeleton most commonly affected (distal radius, distal ulna, carpus, tarsus, distal tibia); vertebral involvement (discospondylitis-like lesion) causes spinal pain, ataxia, paresis | 20 to 30 percent of symptomatic cases; the most common extrapulmonary dissemination site; bone lesions are the most common cause of diagnostic confusion with osteosarcoma |
| Systemic/Constitutional | Weight loss; anorexia; lethargy; chronic low-grade fever; lymphadenopathy (peripheral and visceral) | Present in most cases with significant disease |
| Skin | Subcutaneous nodules, abscesses, or draining tracts, most commonly overlying lytic bone lesions; ulcerated granulomatous skin lesions; cutaneous dissemination without underlying bone involvement is less common than in blastomycosis | Uncommon as a primary presenting sign; more commonly secondary to underlying bone lesion extension through the cortex and skin |
| Cardiac | Pericardial effusion; myocarditis; arrhythmias; right-sided heart failure signs (ascites, jugular venous distension); pericardial effusion from coccidioidomycosis is a recognized syndrome in dogs in endemic areas | Uncommon but clinically important; pericardial effusion requiring pericardiocentesis occurs in some dogs; cardiac coccidioidomycosis can occur without obvious pulmonary or skeletal disease |
| CNS | Meningitis; granulomatous encephalitis; seizures; ataxia; altered mentation; vestibular signs; spinal cord compression from vertebral body lytic lesions causing paresis or paralysis | Uncommon; CNS coccidioidomycosis carries the worst prognosis; fluconazole is preferred for CNS disease due to better penetration |
| Ocular | Uveitis; chorioretinitis; retinal detachment; secondary glaucoma | Uncommon; reported in dogs with systemic dissemination |
Diagnosis
Serology (Primary Diagnostic Method)
Unlike blastomycosis (where cytology is the fastest diagnostic method) and histoplasmosis (where rectal scraping or urine antigen is used), serology is the cornerstone of coccidioidomycosis diagnosis in dogs:
- AGID (Agar Gel Immunodiffusion): detects IgM antibodies (early infection, often positive within 1 to 3 weeks of infection) and IgG antibodies (established or chronic infection) in separate bands; a positive AGID IgM or IgG result in a dog from an endemic area with compatible clinical signs is highly supportive of coccidioidomycosis; AGID sensitivity is approximately 75 to 90 percent in dogs with active clinical disease
- Complement Fixation (CF) titer: quantitative titer expressed as a dilution ratio (1:2, 1:4, 1:8, 1:16, 1:32, etc.); CF titers above 1:16 are generally associated with more severe or disseminated disease; serial CF titers are the most useful monitoring tool during treatment; a declining CF titer during treatment confirms therapeutic response; a rising titer during or after treatment indicates treatment failure or relapse
- Latex Agglutination Test (LAT): rapid screening test for IgM; useful for early infection detection; less specific than AGID
- Urine/Serum Coccidioides Antigen EIA (MiraVista): detects shed galactomannan antigen; particularly useful in severely immunosuppressed dogs who may fail to mount detectable antibody responses despite active infection (seronegative disease); cross-reactivity with Histoplasma antigen occurs
Cytology and Histopathology
Direct identification of Coccidioides spherules in cytological or histological preparations is definitive; spherules are the largest tissue structure produced by any pathogenic fungus and are immediately recognizable at low magnification (10x to 20x objective): large round to oval thick-walled structures 60 to 200 micrometers in diameter, filled with smaller endospores (the “bag of marbles” or “soccer ball” appearance); mature spherules with endospores are unmistakable; early spherules without visible endospores may be confused with other large round structures but are recognizable by their size and thick PAS or GMS-positive wall; cytological specimens can be obtained from draining skin tracts or subcutaneous nodules (easy access, excellent diagnostic yield), bronchoalveolar lavage fluid, pleural or pericardial effusion, fine-needle aspirate of enlarged lymph nodes or bony lesions (with care), and CSF (for CNS disease, though spherules in CSF are less commonly found).
Thoracic and Skeletal Radiography
Thoracic radiographs in dogs with pulmonary coccidioidomycosis may show a focal alveolar pattern (consolidation), a diffuse interstitial infiltrate, pleural effusion, or hilar lymphadenopathy; the pulmonary radiographic pattern is less characteristic than the miliary nodular pattern of blastomycosis and is more variable; skeletal radiography of suspected bony lesions shows a combination of lytic destruction (irregular cortical destruction, medullary cavity lysis) and periosteal new bone formation (aggressive periosteal reaction); the combination of cortical lysis, periosteal reaction, and soft tissue swelling in a dog from Arizona, California, or New Mexico is coccidioidomycosis until proven otherwise, and serology should precede bone biopsy; a bone biopsy in a dog with coccidioidomycosis risks seeding the biopsy track with organisms and is unnecessary when serology confirms the diagnosis.
Treatment
Fluconazole (First-Line Therapy)
Fluconazole at 5 to 10 mg/kg orally once daily is the preferred first-line treatment for coccidioidomycosis in dogs; it is preferred over itraconazole for this specific disease for the following reasons:
- Bone penetration: fluconazole achieves good concentrations in bone tissue and synovial fluid, making it more effective for the osseous dissemination that is so common in canine coccidioidomycosis; itraconazole’s bone penetration is significantly lower
- CNS penetration: CSF concentrations of fluconazole are approximately 70 to 80 percent of plasma concentrations; itraconazole penetrates CSF poorly
- No food requirement: fluconazole is water-soluble and does not require a fatty meal for absorption; this simplifies administration in anorexic or ill dogs
- Lower hepatotoxicity risk: fluconazole has a more favorable hepatotoxicity profile in dogs compared to itraconazole
- Bioavailability consistency: generic fluconazole capsules and tablets have consistent bioavailability, unlike generic itraconazole formulations
Minimum treatment duration: 6 months for uncomplicated pulmonary coccidioidomycosis; 12 months or longer for osseous dissemination; 24 months or longer (potentially lifelong) for CNS or spinal involvement; treatment decisions should be guided by clinical response, radiographic improvement, and serial serological titers rather than a fixed calendar endpoint.
Itraconazole (Alternative)
Itraconazole at 5 mg/kg orally once daily with a fatty meal is an alternative for dogs that cannot tolerate fluconazole or where fluconazole is unavailable; it is less preferred for osseous and CNS disease because of lower penetration into those compartments; the same bioavailability concerns apply as for other dimorphic fungal diseases (Sporanox brand capsules preferred over generic formulations); monthly liver enzyme monitoring is required.
Voriconazole (CNS Disease)
Voriconazole, a second-generation triazole, is an option for CNS coccidioidomycosis that fails fluconazole; it has excellent CNS penetration and activity against Coccidioides; however, it is more expensive than fluconazole and has a less well-established dosing protocol in dogs; voriconazole toxicity in dogs includes neurological signs (visual disturbances have been described in cats), and its use should be supervised by an internal medicine or infectious disease specialist.
Amphotericin B (Severe Disease)
Amphotericin B (lipid formulation preferred) is reserved for rapidly progressive pulmonary or disseminated disease, CNS coccidioidomycosis refractory to azoles, and cases where rapid fungicidal activity is urgently needed; it is given by IV infusion with renal monitoring and followed by long-term oral azole consolidation therapy.
Monitoring During Treatment
Serial CF titers every 2 to 3 months during treatment are the most practical monitoring tool; a declining CF titer (by two or more dilution steps) indicates therapeutic response; stable or rising titers despite treatment suggest inadequate drug levels, poor absorption, or a resistant isolate; serum fluconazole concentration measurement (therapeutic drug monitoring) is available through some reference laboratories and can confirm adequate drug exposure in dogs that fail to improve clinically despite appropriate dosing.
US Cost Overview for Valley Fever
| Service | Typical US Cost |
|---|---|
| Veterinary examination | $60 to $150 |
| Coccidioides AGID serology (IgM and IgG) | $60 to $120 |
| Complement fixation titer | $40 to $80 |
| MiraVista Coccidioides antigen EIA | $60 to $100 |
| Complete blood count and chemistry panel | $150 to $300 |
| Thoracic radiographs (two views) | $150 to $350 |
| Skeletal radiographs (affected limb) | $100 to $250 |
| Echocardiogram (pericardial effusion evaluation) | $400 to $900 |
| Cytology from draining tract or aspirate | $80 to $200 |
| Fluconazole (12-month course, 30 kg dog at 5 mg/kg) | $120 to $400 |
| Itraconazole (12-month course, 30 kg dog) | $500 to $1,200 |
| Monthly liver enzyme monitoring | $80 to $150 per recheck |
| Serial CF titers (every 2 to 3 months) | $40 to $80 per titer |
| Pericardiocentesis (if pericardial effusion) | $500 to $1,500 |
Age-Specific Considerations
Puppies (Under 12 Months)
- Young dogs in Arizona and California endemic areas face significant coccidioidomycosis exposure risk from their first outdoor activities; puppy socialization classes, dog parks, and backyard play in desert-landscape yards all involve soil exposure in heavily endemic areas; a puppy that develops persistent cough, fever, or lethargy within 1 to 6 weeks of starting outdoor activities in Phoenix or Tucson should have valley fever serology performed as part of the initial workup, even if the presenting signs suggest a simpler respiratory infection
- Puppies exposed during the primary immunological development period may have more severe primary pulmonary disease than adult dogs because their adaptive immune responses, particularly Th1-polarized cell-mediated immunity against fungi, are less experienced; however, puppies that recover from primary pulmonary coccidioidomycosis often develop strong protective immunity, similar to the pattern seen in humans in endemic areas who become naturally immune after primary infection
- Fluconazole dosing in puppies follows the same weight-based protocol as adult dogs and is generally well tolerated; the treatment duration (6 months minimum for pulmonary disease) represents a large fraction of a puppy’s first year; owner education about the importance of completing the full treatment course and monitoring CF titers is essential to prevent premature discontinuation when the puppy feels better after the first few weeks of treatment
Adult Dogs (1 to 8 Years)
- Active adult dogs in Arizona and California, particularly those used for hiking, hunting, trail running, or off-leash desert activities, face the highest cumulative environmental exposure to Coccidioides; dust storms (haboobs) that occur in central Arizona between July and September (monsoon season) are associated with spikes in valley fever cases because they aerosolize large quantities of soil particles; keeping dogs indoors during and immediately after dust storms is a practical risk reduction strategy in endemic areas
- The most important diagnostic pitfall in adult dogs with osseous coccidioidomycosis is misdiagnosis as osteosarcoma; both conditions produce aggressive lytic bone lesions with periosteal reaction on radiographs, both occur in large-breed dogs, and both can occur in the distal appendicular skeleton; however, osteosarcoma in dogs rarely produces draining skin tracts (which are characteristic of fungal osteomyelitis), and coccidioidomycosis tends to produce multisite bone lesions more often than osteosarcoma; valley fever serology should be performed before bone biopsy in any large-breed dog from an endemic area with a lytic bone lesion, because a positive AGID or CF titer makes biopsy unnecessary and bone biopsy in an infected dog risks seeding the biopsy track
- Adult dogs that relocate from endemic areas (Arizona, California) to non-endemic areas can develop clinical coccidioidomycosis weeks to months after relocation; the incubation period from exposure to clinical illness can range from 1 to 4 weeks for primary pulmonary disease and much longer for disseminated disease; a dog recently relocated from the Southwest with unexplained respiratory illness, bone pain, or other compatible signs should have valley fever serology regardless of current location
Senior Dogs (9 Years and Older)
- Senior dogs with concurrent immunosuppressive conditions (Cushing’s disease, diabetes mellitus, chronic corticosteroid use for arthritis or allergies) are at elevated risk for progressive or disseminated coccidioidomycosis; the cell-mediated immune response that normally contains primary pulmonary infection and prevents dissemination depends on intact T-lymphocyte function; conditions or medications that impair T-cell function allow dissemination to proceed despite adequate exposure history; a senior dog on chronic corticosteroids in an endemic area who develops fever, weight loss, cough, or bone pain should be evaluated for valley fever before increasing the steroid dose or adding other immunosuppressants
- Senior dogs with pre-existing cardiac disease face compounded risk from coccidioidomycosis pericardial effusion; pericardial effusion from coccidioidomycosis in a dog with pre-existing myxomatous mitral valve disease or dilated cardiomyopathy can precipitate acute cardiac tamponade (compression of the heart by fluid within the pericardial sac, preventing adequate cardiac filling and output); any senior dog from an endemic area with acute-onset exercise intolerance, muffled heart sounds, jugular vein distension, and ascites should have emergency echocardiography to evaluate for pericardial effusion, which requires pericardiocentesis regardless of the underlying cause
- Fluconazole is generally well tolerated in senior dogs with normal hepatic and renal function; renal dosage adjustment is necessary in dogs with significantly reduced glomerular filtration rate because fluconazole is primarily renally excreted; baseline serum creatinine and urine specific gravity assessment before starting fluconazole, with periodic renal function monitoring during long-term treatment, is appropriate in senior dogs with any suspicion of chronic kidney disease
Myths and Facts About Valley Fever in Dogs
My dog’s X-ray shows bone destruction that looks like osteosarcoma, so it must be bone cancer since valley fever only causes lung disease.
Osseous dissemination occurs in approximately 20 to 30 percent of dogs with symptomatic coccidioidomycosis, making bone disease one of the most common manifestations of valley fever in dogs, not a rare exception. The radiographic pattern of coccidioidomycosis bone involvement (cortical lysis, periosteal new bone, soft tissue swelling, draining tracts) closely mimics osteosarcoma. Coccidioides AGID serology should be performed before bone biopsy in any dog from an endemic area with a lytic bone lesion; a positive titer confirms coccidioidomycosis, eliminates the need for biopsy, and guides appropriate antifungal treatment.
My dog tested positive for valley fever antibodies but has no symptoms, so the positive test is a lab error and no treatment is needed.
Seropositivity in a clinically normal dog in an endemic area most likely reflects prior exposure and a successful immune response that contained the infection without clinical illness; this is the normal and expected outcome in the majority of exposed dogs. A positive AGID or low CF titer in an asymptomatic dog from an endemic area does not necessarily require treatment. However, the decision to treat or monitor requires veterinary evaluation: if a dog is seropositive and has subtle signs (mild lethargy, decreased activity, mild weight loss) that the owner has attributed to aging or the environment, a more thorough examination may reveal early disseminated disease that warrants treatment.
Valley fever is only a disease of Arizona and California, so my dog in Colorado or Texas cannot have it.
The endemic range of Coccidioides extends into west Texas (Chihuahuan Desert), southern Nevada (Las Vegas area), and southwestern Utah, and published data show range expansion into Oregon and Washington as temperatures rise. More importantly, millions of dogs travel between states, and dogs relocated from Arizona or California to Colorado or other non-endemic states can develop clinical coccidioidomycosis weeks to months after the move (incubation period from exposure to clinical disease can be weeks to months for disseminated disease). A dog with unexplained bone pain, respiratory disease, or weight loss that recently moved from the Southwest deserves valley fever serology regardless of current location.
Red Flags: Signs Requiring Same-Day or Emergency Evaluation
- Acute-onset severe respiratory distress in a dog from an endemic area with suspected or known coccidioidomycosis: massive pulmonary involvement can cause respiratory failure; labored breathing, extended neck posture, open-mouth breathing, or blue-tinged gums require immediate emergency evaluation and oxygen support; some of these dogs need amphotericin B rather than oral fluconazole for rapid fungicidal activity during the acute phase
- Sudden onset of weakness, exercise intolerance, muffled heart sounds, or abdominal distension in a dog from an endemic area: pericardial effusion from cardiac coccidioidomycosis can cause cardiac tamponade, a life-threatening compression of the heart by accumulated fluid that prevents adequate cardiac output; emergency echocardiography and pericardiocentesis may be necessary; pericardial effusion in a dog from Arizona or California should always prompt valley fever serology and pericardial fluid analysis for Coccidioides spherules
- Acute-onset hindlimb paresis or paralysis in a dog with confirmed or suspected coccidioidomycosis: vertebral body coccidioidomycosis producing spinal cord compression is a neurological emergency; urgent spinal imaging (CT or MRI) and evaluation of surgical decompression versus medical management are needed; spinal coccidioidomycosis requires prolonged antifungal therapy (often 18 to 24 months or lifelong) and carries a guarded prognosis for recovery of neurological function
- Seizures or acute altered mentation in a dog from an endemic area: CNS coccidioidomycosis (meningitis, granulomatous encephalitis) requires immediate neurological evaluation including CSF analysis and MRI; meningeal coccidioidomycosis carries a high mortality rate and requires aggressive treatment including fluconazole at doses toward the higher end of the range (10 mg/kg daily), potentially with voriconazole or amphotericin B added for refractory cases
- A draining tract over a limb bone in a dog from Arizona or California that has been empirically treated as a bacterial wound infection without improvement: draining tracts overlying lytic bone lesions are highly characteristic of fungal osteomyelitis (coccidioidomycosis or blastomycosis); failure to respond to antibiotics should prompt immediate valley fever serology and cytological examination of the draining material; continuing antibiotics while a fungal infection progresses unchecked wastes critical treatment time
Frequently Asked Questions About Valley Fever in Dogs
What is valley fever in dogs?
Valley fever (coccidioidomycosis) is a fungal infection caused by Coccidioides immitis (California) and C. posadasii (Arizona, New Mexico, Texas), found in the desert soil of the American Southwest. Dogs inhale microscopic spores (arthroconidia) released when soil is disturbed; these convert to large spherules in the lungs that can disseminate to bone, skin, the heart, and the nervous system. Arizona has the highest case burden, with up to 70 percent of adult dogs in central Arizona being seropositive.
What are the symptoms of valley fever in dogs?
Cough, fever, weight loss, and lethargy are the most common signs of primary pulmonary disease. In dogs with bone dissemination (20 to 30 percent of symptomatic cases), there is lameness, soft tissue swelling over the affected bone, and sometimes draining skin tracts; bone lesions mimic osteosarcoma radiographically. Pericardial effusion, CNS signs (seizures, ataxia), and skin lesions occur in some dogs with disseminated disease.
How is valley fever diagnosed in dogs?
Serology is the primary diagnostic tool: the Coccidioides AGID test detects IgM (early infection) and IgG (established infection) antibodies, and the complement fixation (CF) titer provides a quantitative measure of disease severity and treatment response. The urine/serum Coccidioides antigen EIA (MiraVista) adds sensitivity. Direct identification of large spherules with endospores on cytology from draining tracts, lymph node aspirates, or BAL fluid is definitive. Serology should precede bone biopsy in dogs with lytic bone lesions from endemic areas.
What is the treatment for valley fever in dogs?
Fluconazole 5 to 10 mg/kg once daily is the first-line treatment, preferred over itraconazole because of better bone and CNS penetration and consistent oral bioavailability without food requirements. Minimum treatment duration is 6 months for pulmonary disease and 12 months or longer for bone dissemination; spinal or CNS involvement may require lifelong treatment. Serial CF titers every 2 to 3 months guide treatment duration. Amphotericin B is reserved for severe or rapidly progressive cases.
Where is valley fever most common in dogs?
Arizona (particularly the Phoenix and Tucson metropolitan areas in Maricopa and Pima counties) has the highest prevalence of coccidioidomycosis in the US; some estimates place valley fever as the most common infectious disease of dogs in the Phoenix area. The San Joaquin Valley of California, the Mojave Desert, and the Chihuahuan Desert of New Mexico and west Texas are also highly endemic. The geographic range is expanding northward as temperatures rise.
Can valley fever spread from my dog to me?
No. The tissue spherule form of Coccidioides found in infected dogs is not directly transmissible to humans through contact with an infected dog. Both dogs and humans acquire valley fever from the same source: inhaling arthroconidia from contaminated desert soil. However, pus or exudate from draining skin tracts of an infected dog could theoretically contain spherules or endospores; wearing gloves when handling draining lesions and washing hands after contact is a reasonable precaution, though documented cases of transmission in this manner are extremely rare.
What is the prognosis for dogs with valley fever?
Dogs with uncomplicated pulmonary coccidioidomycosis treated with fluconazole have a good prognosis (survival rates above 80 percent with appropriate treatment). Dogs with osseous dissemination that is diagnosed early and treated with prolonged fluconazole also have reasonably good outcomes, though treatment may last 12 to 24 months and some dogs require lifelong suppressive therapy. CNS coccidioidomycosis, cardiac involvement, and dissemination during immunosuppressive therapy carry guarded to poor prognoses.
For more guides on keeping your dog healthy, browse all our Dog Health articles.
Explore Dog Health Articles